To promote clinical trial digital transformation, we have entered into a capital and business alliance with Medley M3 and raised funds from DG Resona.
Press
Strategic partnership with eCOA/DCT vendor Xincere to attract more clinical trials to Japan
Attracting clinical trials to Japan in Asia and globally and strengthening DCT and digital clinical trial infrastructure
Buzzreach Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Takateru Inokawa; hereinafter referred to as “Buzzreach”) has entered into a strategic partnership with Xincere Med Tech Inc. (Head office: Shanghai; Founder & CEO: Kevin Lin; hereinafter referred to as “Xincere”), a leading company in the fields of decentralized clinical trials (hereinafter referred to as DCT) and electronic clinical outcome assessment (eCOA).
Through this partnership, the two companies will strengthen collaboration in the areas of technology, platforms, and patient recruitment, with the aim of attracting clinical trials to Japan in Asian and global markets, and accelerating and improving the quality of DCT and digital clinical trials.
Related Articles
-
-
We have begun offering the first DCT business management function on our clinical trial and clinical research business support platform, StudyWorks®.
-
Using “smt,” Boehringer Ingelheim Japan begins supporting the disclosure of clinical trial information
-
Vaccination rates among the elderly are declining – latest report
-
Interviews with medical institutions that have adopted “StudyWorks”: Part 1 (Kanazawa University Hospital)
-
The “Partner Site” network now covers 29 diseases and exceeds 737 facilities
-
“StudyWorks” now installed at over 30 facilities, and now also supports DCT business management